In prostate cancer, E-cadherin and Snail levels can be measured to assess disease prognosis and can be used as therapeutic targets to prevent metastatic progression [57].A previous study reported that E-cadherin expression was decreased in the uterus of mice and in human adenomyotic lesions [56]. This evidence concerns the gene CDH1 and prostate carcinoma.